- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05903066
TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1) (TRENCH 1)
TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD).
Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Number of patients : 210 patients, in 14 sites (only one investigator per site), 15 patients per site, 5 patients per grade of transmural healing based on the appraisal of a local reader pair (a gastroenterologist and a radiologist).
Recruitment period : 2 years
Primary Endpoint : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Secondary Endpoints :
- To analyze intra- and inter-observer variability of radiological findings.
- To analyze intra- and inter-observer variability of TH definitions in CD.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, 4000
- CHU de Liège
-
-
-
-
-
Amiens, France, 80054
- CHU Amiens-Picardie (site Sud)
-
Bordeaux, France, 33600
- CHU de Bordeaux - Hôpital Haut-Lévêque
-
Boulogne-Billancourt, France, 92100
- APHP - Hôpital Ambroise Paré
-
Clermont-Ferrand, France, 63003
- CHU de Clermont-Ferrand - Hôpital d'Estaing
-
Lille, France, 59037
- CHRU de Lille - Hôpital Claude Huriez
-
Limoges, France, 87000
- CHU Limoges Dupuytren
-
Marseille, France, 13015
- AP-HM - Hôpital Nord
-
Montpellier, France, 34295
- CHU de Montpellier - Hôpital Saint Eloi
-
Nantes, France, 44093
- CHU de Nantes
-
Nîmes, France, 30029
- CHU de Nîmes - Hôpital Carémeau
-
Pierre-Bénite, France, 69475
- Hospices Civils de Lyon
-
Rennes, France, 35033
- CHU Rennes - Hôpital Pontchaillou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients diagnosed with CD for more than 6 months with histological confirmation available in his medical record, with an indication for MRE based on routine clinical practice validated by the treating physician
Description
Inclusion Criteria:
- ≥ 18 years of age
- Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record.
- Indication for MRE based on routine clinical practice validated by the treating physician
- Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…).
- The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study.
- A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.
Exclusion Criteria:
- Pregnancy during the study
- People unable to give consent (because of their physical or mental state)
- Absence of written consent
- Ulcerative colitis or unclassified IBD
- Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy.
- Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve)
- Severe obstructive symptoms
- Symptomatic intra-abdominal abscess
- Contraindication for MRI
- Isolated perianal disease without luminal location
- MRE images of poor quality, based on previously defined criteria
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Time Frame: Day 1
|
An index (depth of remission) or score (grade of remission) will be constructed through multiple linear or logistic mixed regression models. |
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra- and inter-observer variability of lesions observed per segment during MRE in CD
Time Frame: Day 1
|
Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items. |
Day 1
|
|
Intra- and inter-observer variability of depth and grade of global transmural healing in CD
Time Frame: Day 1
|
Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items. |
Day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sophie GEYL, CHU Limoge Dupuytren
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GETAID-2022-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.